Journal
TRANSPLANTATION
Volume 75, Issue 9, Pages 1594-1596Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/01.TP.0000058748.00707.88
Keywords
-
Categories
Ask authors/readers for more resources
Background. Islet transplantation has become a clinical reality; however, before it can be extended to young juvenile diabetics an unlimited supply of tissue is needed and the use of chronic immunosuppression should be eliminated. This study was designed to determine whether Sertoli cells can immunoprotect islet xenografts. Methods. Lewis rat islets were cotransplanted with Balb/c Sertoli cells in diabetic Balb/c mice treated with one injection of anti-mouse lymphocyte serum (ALS). Results. When islets were transplanted alone, in combination with Sertoli cells, or in combination with ALS, mean graft survival times were 10.9+/-0.8, 14.0+/-1.2, or 12.2+/-0.7, respectively. When islets were combined with Sertoli cells and ALS, mean graft survival time increased to 64.9+/-8.1. Conclusions. Sertoli cells are able to prolong the survival of islet xenografts when combined with ALS, thereby supporting their use as a means to immunoprotect cellular grafts such as islets for the treatment of type 1 diabetes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available